Preclinical evaluation of the abuse potential of Pitolisant, a histamine H3 receptor inverse agonist/antagonist compared with Modafinil

British Journal of Pharmacology

Volumn 169, Issue 3, 2013, Pages 632-644

  Uguen, M ^a   Perrin, D ^a   Belliard, S ^a   Ligneau, X ^a   Beardsley, P M ^b   Lecomte, J M ^a   Schwartz, J C ^a  

^a Bioprojet Biotech   (France)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

conditioned place preference; discrimination; drug abuse; H3 receptor; histamine; monkeys; Pitolisant; rodents; self administration; sensitization

Indexed keywords

BF 2 649; COCAINE; DEXAMPHETAMINE; HISTAMINE H3 RECEPTOR ANTAGONIST; HISTAMINE H3 RECEPTOR INVERSE AGONIST; HISTAMINERGIC RECEPTOR AFFECTING AGENT; MODAFINIL; PITOLISANT; PSYCHOSTIMULANT AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG ABUSE; DRUG DEPENDENCE; DRUG EFFECT; DRUG INDICATION; DRUG SELF ADMINISTRATION; HAPLORHINI; IN VIVO STUDY; LOCOMOTION; NONHUMAN; NUCLEUS ACCUMBENS; PLACE PREFERENCE; PRIMATE; PRIORITY JOURNAL; REPEATED DRUG DOSE; RODENT; SENSITIZATION; SINGLE DRUG DOSE;

ANIMALS; BEHAVIOR, ADDICTIVE; BEHAVIOR, ANIMAL; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; DRUG EVALUATION, PRECLINICAL; DRUG INVERSE AGONISM; DRUGS, INVESTIGATIONAL; HISTAMINE AGONISTS; HISTAMINE ANTAGONISTS; MACACA MULATTA; MALE; MICE; MOTOR ACTIVITY; NUCLEUS ACCUMBENS; PIPERIDINES; RATS; RECEPTORS, HISTAMINE H3; WAKEFULNESS-PROMOTING AGENTS;

EID: 84877837311     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12149     Document Type: Article

References (60)

1. Andersen ML, Kessler E, Murnane KS, McClung JC, Tufik S, Howell LL, (2010). Dopamine transporter-related effects of modafinil in rhesus monkeys. Psychopharmacology (Berlin) 210: 439-448.
2. Barbier AJ, Berridge C, Dugovic C, Laposky AD, Wilson SJ, Boggs J, et al. (2004). Acute wake-promoting actions of JNJ-5207852, a novel, diamine-based H3 antagonist. Br J Pharmacol 143: 649-661.
3. Beardsley PM, Hayes BA, Balster RL, (1990). The self-administration of MK-801 can depend upon drug-reinforcement history, and its discriminative stimulus properties are phencyclidine-like in rhesus monkeys. J Pharmacol Exp Ther 252: 953-959.
4. Bernardi RE, Lewis JR, Lattal KM, Berger SP, (2009). Modafinil reinstates a cocaine conditioned place preference following extinction in rats. Behav Brain Res 204: 250-253.
5. Brabant C, Charlier Y, Quertemont E, Tirelli E, (2005). The H3 antagonist thioperamide reveals conditioned preference for a context associated with an inactive small dose of cocaine in C57BL/6J mice. Behav Brain Res 160: 161-168.
6. Brabant C, Quertemont E, Anaclet C, Lin JS, Ohtsu H, Tirelli E, (2007). The psychostimulant and rewarding effects of cocaine in histidine decarboxylase knockout mice do not support the hypothesis of an inhibitory function of histamine on reward. Psychopharmacology (Berlin) 190: 251-263.
7. Clapham J, Kilpatrick GJ, (1994). Thioperamide, the selective histamine H3 receptor antagonist, attenuates stimulant-induced locomotor activity in the mouse. Eur J Pharmacol 259: 107-114.
8. Deroche-Gamonet V, Darnaudéry M, Bruins-Slot L, Piat F, Le Moal M, Piazza PV, (2002). Study of the addictive potential of modafinil in naive and cocaine-experienced rats. Psychopharmacology (Berlin) 161: 387-395.
9. Di Chiara G, Bassareo V, Fenu S, De Luca MA, Spina L, Cadoni C, et al. (2004). Dopamine and drug addiction: the nucleus accumbens shell connection. Neuropharmacology 47: 227-241.
10. Dopheide MM, Morgan RE, Rodvelt KR, Schachtman TR, Miller DK, (2007). Modafinil evokes striatal [3H]dopamine release and alters the subjective properties of stimulants. Eur J Pharmacol 568: 112-123.
11. Duarte C, Lefebvre C, Chaperon F, Hamon M, Thiébot MH, (2003). Effects of a dopamine D3 receptor ligand, BP 897, on acquisition and expression of food-, morphine-, and cocaine-induced conditioned place preference, and food-seeking behavior in rats. Neuropsychopharmacology 28: 1903-1915.
12. Esbenshade TA, Fox GB, Krueger KM, Miller TR, Kang CH, Denny LI, et al. (2005). Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2- Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties. J Pharmacol Exp Ther 313: 165-175.
13. European Medicines Agency EMA/725532/2010 rev (2011). Questions and answers on the review of medicines containing modafinil. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Referrals-document/ Modafinil-31/WC500099177.pdf (accessed 3/26/2013).
14. Ferraro L, Tanganelli S, O'Connor WT, Antonelli T, Rambert F, Fuxe K, (1996). The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism. Eur J Pharmacol 306: 33-39.
15. Fox GB, Esbenshade TA, Pan JB, Radek RJ, Krueger KM, Yao BB, et al. (2005). Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2- Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther 313: 176-190.
16. Galici R, Rezvani AH, Aluisio L, Lord B, Levin ED, Fraser I, et al. (2011). JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats. Psychopharmacology (Berlin) 214: 829-841.
17. Gellert VF, Holtzman SG, (1978). Development and maintenance of morphine tolerance and dependence in the rat by scheduled access to morphine drinking solutions. J Pharmacol Exp Ther 205: 536-546.
18. Gold LH, Balster RL, (1996). Evaluation of the cocaine-like discriminative stimulus effects and reinforcing effects of modafinil. Psychopharmacology (Berlin) 126: 286-292.
19. Goodchild RE, Court JA, Hobson I, Piggott MA, Perry RH, Ince P, et al. (1999). Distribution of histamine H3-receptor binding in the normal human basal ganglia: comparison with Huntington's and Parkinson's disease cases. Eur J Neurosci 11: 449-456.
20. Haas H, Panula P, (2003). The role of histamine and the tuberomamillary nucleus in the nervous system. Nat Rev Neurosci 4: 121-130.
21. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
22. Kolhatkar R, Cook CD, Ghorai SK, Deschamps J, Beardsley PM, Reith ME, et al. (2004). Further structurally constrained analogues of cis-(6- benzhydrylpiperidin-3-yl)benzylamine with elucidation of bioactive conformation: discovery of 1,4-diazabicyclo[3.3.1]nonane derivatives and evaluation of their biological properties for the monoamine transporters. J Med Chem 47: 5101-5113.
23. Komater VA, Browman KE, Curzon P, Hancock AA, Decker MW, Fox GB, (2003). H3 receptor blockade by thioperamide enhances cognition in rats without inducing locomotor sensitization. Psychopharmacology (Berlin) 167: 363-372.
24. Kuhne S, Wijtmans M, Lim HD, Leurs R, de, Esch IJ, (2011). Several down, a few to go: histamine H3 receptor ligands making the final push towards the market? Expert Opin Investig Drugs 20: 1629-1648.
25. Lazewska D, Kiec-Kononowicz K, (2010). Recent advances in histamine H3 receptor antagonists/inverse agonists. Expert Opin Ther Pat 20: 1147-1169.
26. Le Foll B, Sokoloff P, Stark H, Goldberg SR, (2005). Dopamine D3 receptor ligands block nicotine-induced conditioned place preferences through a mechanism that does not involve discriminative-stimulus or antidepressant-like effects. Neuropsychopharmacology 30: 720-730.
27. Leurs R, Vischer HF, Wijtmans M, de, Esch IJ, (2011). En route to new blockbuster anti-histamines: surveying the offspring of the expanding histamine receptor family. Trends Pharmacol Sci 32: 250-257.
28. Ligneau X, Landais L, Perrin D, Piriou J, Uguen M, Denis E, et al. (2007a). Brain histamine and schizophrenia: potential therapeutic applications of H3-receptor inverse agonists studied with BF2.649. Biochem Pharmacol 73: 1215-1224.
29. Ligneau X, Perrin D, Landais L, Camelin JC, Calmels TP, Berrebi-Bertrand I, et al. (2007b). BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: preclinical pharmacology. J Pharmacol Exp Ther 320: 365-375.
30. -/- mice and patients. Neurobiol Dis 30: 74-83.
31. Lin JS, Sergeeva OA, Haas HL, (2011). Histamine H3 receptors and sleep-wake regulation. J Pharmacol Exp Ther 336: 17-23.
32. Loland CJ, Mereu M, Okunola OM, Cao J, Prisinzano TE, Mazier S, et al. (2012). R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse. Biol Psychiatry 72: 405-413.
33. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
34. Medhurst AD, Atkins AR, Beresford IJ, Brackenborough K, Briggs MA, Calver AR, et al. (2007). GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther 321: 1032-1045.
35. Mori T, Narita M, Onodera K, Suzuki T, (2002). Modulation of the discriminative stimulus effects of cocaine and methamphetamine by the histaminergic system. Nihon Shinkei Seishin Yakurigaku Zasshi 22: 73-78.
36. Morisset S, Rouleau A, Ligneau X, Gbahou F, Tardivel-Lacombe J, Stark H, et al. (2000). High constitutive activity of native H3 receptors regulates histamine neurons in brain. Nature 408: 860-864.
37. Munzar P, Nosál R, Goldberg SR, (1998). Potentiation of the discriminative-stimulus effects of methamphetamine by the histamine H3 receptor antagonist thioperamide in rats. Eur J Pharmacol 363: 93-101.
38. Munzar P, Tanda G, Justinova Z, Goldberg SR, (2004). Histamine H3 receptor antagonists potentiate methamphetamine self-administration and methamphetamine-induced accumbal dopamine release. Neuropsychopharmacology 29: 705-717.
39. Newman JL, Negus SS, Lozama A, Prisinzano TE, Mello NK, (2010). Behavioral evaluation of modafinil and the abuse-related effects of cocaine in rhesus monkeys. Exp Clin Psychopharmacol 18: 395-408.
40. Nguyen TL, Tian YH, You IJ, Lee SY, Jang CG, (2011). Modafinil-induced conditioned place preference via dopaminergic system in mice. Synapse 65: 733-741.
41. Nuutinen S, Karlstedt K, Aitta-Aho T, Korpi ER, Panula P, (2010). Histamine H3 receptor-dependent mechanisms regulate ethanol stimulation and conditioned place preference in mice. Psychopharmacology 208: 75-86.
42. Nuutinen S, Lintunen M, Vanhanen J, Ojala T, Rozov S, Panula P, (2011a). Evidence for the role of histamine H3 receptor in alcohol consumption and alcohol reward in mice. Neuropsychopharmacology 36: 2030-2040.
43. Nuutinen S, Vanhanen J, Pigni MC, Panula P, (2011b). Effects of histamine H3 receptor ligands on the rewarding, stimulant and motor-impairing effects of ethanol in DBA/2J mice. Neuropharmacology 60: 1193-1199.
44. Okuda T, Zhang D, Shao H, Okamura N, Takino N, Iwamura T, et al. (2009). Methamphetamine- and 3,4-methylenedioxymethamphetamine-induced behavioral changes in histamine H3-receptor knockout mice. J Pharmacol Sci 111: 167-174.
45. Paterson NE, Fedolak A, Olivier B, Hanania T, Ghavami A, Caldarone B, (2010). Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents. Pharmacol Biochem Behav 95: 449-456.
46. Paxinos G, Watson C, (1986). The Rat Brain in Stereotaxic Coordinates. Academic Press: San Diego, CA.
47. Pillot C, Heron A, Cochois V, Tardivel-Lacombe J, Ligneau X, Schwartz JC, et al. (2002). A detailed mapping of the histamine H(3) receptor and its gene transcripts in rat brain. Neuroscience 14: 173-193.
48. Pollard H, Moreau J, Arrang JM, Schwartz JC, (1993). A detailed autoradiographic mapping of histamine H3 receptors in rat brain areas. Neuroscience 52: 169-189.
49. Reichel CM, See RE, (2010). Modafinil effects on reinstatement of methamphetamine seeking in a rat model of relapse. Psychopharmacology (Berlin) 210: 337-346.
50. Reichel CM, See RE, (2012). Chronic modafinil effects on drug-seeking following methamphetamine self-administration in rats. Int J Neuropsychopharmacol 15: 919-929.
51. Schlicker E, Fink K, Detzner M, Göthert M, (1993). Histamine inhibits dopamine release in the mouse striatum via presynaptic H3 receptors. J Neural Transm Gen Sect 93: 1-10.
52. Schwartz JC, (2011). The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol 163: 713-721.
53. Schwartz JC, Arrang JM, Garbarg M, Pollard H, Ruat M, (1991). Histaminergic transmission in the mammalian brain. Physiol Rev 71: 1-51.
54. Shuman T, Cai DJ, Sage JR, Anagnostaras SG, (2012). Interactions between modafinil and cocaine during the induction of conditioned place preference and locomotor sensitization in mice: implications for addiction. Behav Brain Res 235: 105-112.
55. Simon P, Hémet C, Costentin J, (1996). Analysis of stimulant locomotor effects of modafinil in various strains of mice and rats. Fundam Clin Pharmacol 10: 431-435.
56. Tahsili-Fahadan P, Carr GV, Harris GC, Aston-Jones G, (2010). Modafinil blocks reinstatement of extinguished opiate-seeking in rats: mediation by a glutamate mechanism. Neuropsychopharmacology 35: 2203-2210.
57. Tzschentke TM, (1998). Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol 6: 613-672.
58. Volkow ND, Fowler JS, Logan J, Alexoff D, Zhu W, Telang F, et al. (2009). Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 301: 1148-1154.
59. Wuo-Silva R, Fukushiro DF, Borçoi AR, Fernandes HA, Procõpio-Souza R, Hollais AW, et al. (2011). Addictive potential of modafinil and cross-sensitization with cocaine: a pre-clinical study. Addict Biol 16: 565-579.
60. Zolkowska D, Jain R, Rothman RB, Partilla JS, Roth BL, Setola V, et al. (2009). Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther 329: 738-746.